Table 1:
Patient Characteristics before salvage chemotherapy
| All patients | Transplanted | |
|---|---|---|
| Total patients | 60 | 51 |
| Age | ||
| • Median (range) | 35 (19–68) | 35 (19–61) |
| • >60 | 3 (5%) | 1 (2%) |
| Initial Treatment | ||
| • ABVD | 4 (7%) | 4 (8%) |
| • CHOP | 10 (17%) | 6 (12%) |
| • NHL-15 | 20 (33%) | 17 (33%) |
| • R-CHOP | 14 (23%) | 12 (24%) |
| • R-CHOP/ICE | 6 (10%) | 6 (12%) |
| • R-EPOCH | 4 (7%) | 4 (8%) |
| Radiation therapy with primary treatment | ||
| • Yes | 11 (18%) | 8 (16%) |
| • No | 49 (82%) | 43 (84%) |
| Initial Response | ||
| • Relapsed | 25 (42%) | 23 (45%) |
| • Refractory | 35 (58%) | 28 (55%) |
| Disease Bulk at progression | ||
| • Yes | 30 (50%) | 24 (47%) |
| • No | 30 (50%) | 27 (53%) |
| B symptoms at progression | ||
| • Yes | 16 (27%) | 15 (29%) |
| • No | 44 (73%) | 36 (71%) |
| AA stage at progression | ||
| • I-II | 36 (60%) | 31 (61%) |
| • III-IV | 24 (40%) | 20 (39%) |
| LDH at progression | ||
| • Within normal limits | 27 (45%) | 22 (43%) |
| • Elevated | 33 (55%) | 29 (57%) |
| KPS at relapse | ||
| • 80+ | 49 (82%) | 42 (82%) |
| • <80 | 11 (18%) | 9 (18%) |
| Second-line IPI | ||
| • Low | 35 (58%) | 30 (59%) |
| • Low-intermediate | 11 (18%) | 10 (20%) |
| • High-intermediate | 7 (12%) | 7 (14%) |
| • High | 7 (12%) | 4 (8%) |
| Second-line aaIPI | ||
| • Low | 20 (33%) | 16 (31%) |
| • Low-intermediate | 18 (30%) | 16 (31%) |
| • High-intermediate | 16 (27%) | 15 (29%) |
| • High | 6 (10%) | 4 (8%) |
*
R: rituximab. CHOP: cyclophosphamide, hydroxydaunomycin (doxorubicin), Oncovin (vincristine), prednisone. EPOCH: etoposide, prednisone, Oncovin, cyclophosphamide, hydroxydaunomycin. ICE: ifosfamide, carboplatin, etoposide. ABVD: Adriamycin (doxorubicin), bleomycin, vinblastine, dexamethasone. NHL-15: doxorubicin, vincristine, cyclophosphamide.